🇺🇸 FDA
Pipeline program

Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution

160002

Phase 2 small_molecule completed

Quick answer

Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution for Immune Thrombocytopenic Purpura (ITP) is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Immune Thrombocytopenic Purpura (ITP)
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials